The purpose of this study is to evaluate the safety and tolerability of MT-3724 in subjects
with relapsed or refractory B-Cell NHL or relapsed and refractory CLL (Part 1 only) and
relapsed and refractory DLBCL (Part 2 and Part 3). Part 3 evaluates the efficacy of MT-3724.
This is a three-part Phase 2 study
Part 1: (MT-3724 Dose Escalation) Define the maximum tolerated dose (MTD) of MT-3724
Part 2: (MTD Expansion Cohort) Confirm the safety and tolerability of the MTD of MT-3724 in
the MTD Expansion Cohort.
Part 3: (Phase 2 MTD Expansion Cohort) Determine the efficacy of MT-3724 as monotherapy in
subjects with relapsed or refractory DLBCL based on the overall response rate (ORR) by the
revised Lugano Classification for Lymphoma adjusted according to LYRIC.
It is anticipated that up to 100 patients will be enrolled in Part 3. Treatment will continue
for up to six 21 days cycles. If the subject exhibits SD, CR or PR after the end of Cycle 6
and the investigator determines that the benefit-risk ratio is favorable, then the treatment
with MT-3724 may be continued after discussion with the sponsor.
- Men or women, age 18 years or older
• Histology based upon bone marrow biopsies and/or fine needle aspirates as the sole means
of diagnosis are not acceptable. All subtypes of B-cell NHL may be considered for the
MT-3724 dose escalation. Presence of lymphadenopathy and/or splenomegaly with
histopathological evaluation of a lymph node biopsy consistent with CLL.
1. Diffuse large B cell lymphoma (DLBCL). Histology based upon bone marrow biopsies
and/or fine needle aspirates as the sole means of diagnosis are not acceptable.
2. Subjects must have received at least one anti-CD20 antibody containing regimen that
resulted in initial measurable response (partial or complete remission), followed by
3. Life expectancy > 3 months.
4. Eastern Cooperative Oncology Group (ECOG) performance score of ≤2.
5. All lymphoma subjects are required to have measurable disease
6. Patients must be at least 28 days past their last course of lymphoma
7. Received any amount of anti-CD20 MAb therapy within the following periods before the
start of treatment
8. Received any amount of anti-CD20 MAb within the following periods before the start of
1. Rituximab (Rituxan®): if a subject had received any amount of rituximab within
365 days of planned dose day 1 then a serum rituximab level must be negative
(<500 ng/ml) at the screening period
2. Obinutuzumab (Gazyva®): 184 days
3. Ofatumumab (Arzerra®): 88 days
4. ibritumomab tiuxetan (Zevalin®): 10 days
9. Adequate kidney function, assessed by the estimated glomerular filtration rate (eGFR)
10. Female patients of childbearing potential must have a negative serum or urine
pregnancy test within 3 days prior to initiating dosing. Male and female subjects with
reproductive potential must agree to use acceptable contraceptive methods until the
end of study visit.
11. Patients with known central nervous system metastases may be enrolled if they have
received radiotherapy, do not require chronic steroid therapy, have had computed
tomography or magnetic resonance imaging of the brain within 1 month of study entry
that shows stable disease and they have no neurological symptoms other than low grade
1. History of another cancer other than basal cell carcinoma or cervical intraepithelial
neoplasia (CIN; i.e., cervical cancer in situ).
2. Potential subjects cannot have experienced a significant (CTCAE Grade 3 or 4 with or
without neutropenia) infection within 2 weeks of the first dose of MT-3724.
3. Ongoing use of any approved or investigational antineoplastic therapies
4. Systemic corticosteroid therapy at a prednisone dose > 20mg/day (or equivalent) within
14 days prior to study enrollment
5. Potential subjects with pre-existing AEs at screening that are severe or life
threatening by CTCAE, v. 4.03 should not be enrolled.
6. Patients with uncontrolled or severe cardiovascular disease, including myocardial
infarct or unstable angina within 6 months prior to start of study treatment, New York
Heart Association (NYHA) Class II or greater congestive heart failure, serious
arrhythmias requiring medication for treatment, clinically significant pericardial
disease, or cardiac amyloidosis may not be enrolled.
7. Patients with a known history of drug abuse or any chronic neurologic, psychiatric,
endocrine, metabolic, immunologic, hepatic or renal disease (including a history of
hemolytic uremic syndrome) that in the opinion of the Investigator would adversely
affect study participation.
8. Potential subjects must not have received any vaccines for 28 days prior to
administration of their first dose of MT-3724 and should not receive any vaccine
during the study or within 28 days after their last dose of MT-3724. The single
exception to this exclusion is for the annual influenza (flu) vaccine which can be
given up to 14 days prior to first dose.
9. History of hypersensitivity to study drug or to compounds of a similar class, or whose
past history suggests an increased potential for an adverse hypersensitivity reaction
to MT-3724 should not be enrolled.
10. Patients with known active Hepatitis A or C, HIV or a present history of Hepatitis B
11. Potential subjects who have undergone allogeneic hematopoietic stem cell
12. Women who are pregnant or breastfeeding.
13. Potential subjects who have had major surgery within 6 weeks prior to the first dose
of study drug or have major surgery planned during the first 12 weeks post MT 3724
1. Subjects must have relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
according to the Revised European American Lymphoma/World Health Organization
2. Subjects must have received at least 2 standard of care regimens for NHL treatment.
3. Subjects must have at least one tumor lesion at screening
4. Subjects must have life expectancy of >3 months from the start of treatment.
5. Subjects must have ECOG performance status of 0-2.
6. Adequate kidney function
7. QTcF (Fridericia) ≤480 ms determined as the average of three QTcF values from the
triplicate ECG obtained at screening.
8. LVEF ≥45% by MUGA or echocardiogram obtained at screening.
9. Female patients of childbearing potential must not be pregnant.. Male and female
subjects with reproductive potential must agree to use acceptable contraceptive
methods until the end of study visit.
10. Subject must be able to comply with all study-related procedures and medication use.
1. Received any amount of anti-CD20 MAb within the following periods before the start of
1. Rituximab (Rituxan®/MabThera® or rituximab biosimilar): if administered within 12
to 37 weeks before the start of treatment, then serum rituximab level must be
assessed during the screening and confirmed as negative (<500 ng/mL)
2. Obinutuzumab (Gazyva®/Gazyvaro®): 184 days.
3. Ofatumumab (Arzerra®): 88 days.
2. Received approved or investigational treatment for NHL (except anti-CD20 MAb and
radioimmunoconjugates) within 4 weeks before the start of treatment.
Radioimmunoconjugates are excluded within 12 weeks before the start of treatment.
3. Received radiation therapy to target lesions ) within 4 weeks before the start of
treatment, unless the lesions exhibited objective progression between radiation
therapy and screening
a. Palliative radiation therapy to non-target lesions within 4 weeks before the start
of treatment may be permitted at the investigator's discretion.
4. Received systemic immunosuppressive agents (except prescribed corticosteroids at doses
≤20 mg/day prednisone equivalent) within 2 weeks before the start of treatment
5. Received any vaccines except injectable flu (inactivated or recombinant) vaccine
within 4 weeks before the start of treatment, or likely to require any vaccines except
injectable flu vaccine at any time from the start of treatment until 28 days after the
last dose of MT-3724.
6. Received allogeneic stem cell transplant.
7. Current evidence of CTCAE Grade ≥2 (significant) 1 toxicity before the start of
treatment, except for hair loss and those significant toxicities permitted in other
eligibility criteria. Subjects with significant permitted in other eligibility
criteria. Subjects with significant
8. History or current evidence of significant infection, systemic infection or wound
within 2 weeks before the start of treatment.
a. Subjects with significant infection that has stabilized or improved with oral
antibiotics before the start of treatment may be eligible at the investigator's
9. Known or suspected hypersensitivity to the study drug or excipients contained in the
study drug formulation.
10. Current evidence of hypersensitivity or other underlying illness requiring systemic
corticosteroids at doses >20 mg/day prednisone equivalent
11. Patients with known active Hepatitis C, HIV or a present history of Hepatitis B
12. Current evidence of incomplete recovery from surgery or radiotherapy at screening, or
planned surgery or radiotherapy from the start of treatment until the short term
follow-up visit, except minor elective surgery or palliative radiation therapy to
non-target lesions deemed acceptable by the investigator.
13. History of cardiovascular, renal, hepatic or any other disease within ≤3 months before
the start of treatment
14. History of another primary malignancy within the past 3 years (except for ductal
breast cancer in situ, non-melanoma skin cancer, prostate cancer not requiring
treatment, and cervical carcinoma in situ) that required systemic drug therapy or
15. Current evidence of new or growing brain or spinal metastases during screening.
16. Women who are pregnant or breastfeeding.
17. History of non-adherence to the schedule of procedures or medication use